Dong-A to develop molecular diagnostic technology

Dong-A Pharmaceutical and the US-based Nanogea announced on July 22 that both companies have signed a letter of intent for the co-development and commercialization of new molecular diagnostics, using the latter’s proprietary NanoCone-Enabled Atomic Microscopy technology to detect Prostate Specific Antigen at the single molecular level.

Nanogea is a nano-bioscience company focused on commerci...